Evidence map›Paper›PMID 27832441›Full record

ArticleProbiotics and antimicrobial proteins2017

Comparative Effect of the I3.1 Probiotic Formula in Two Animal Models of Colitis.

Violeta Lorén, Josep Manyé, Mari C Fuentes, Eduard Cabré, Isabel Ojanguren, Jordi Espadaler

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Probiotics and antimicrobial proteins, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04696458 (Effects of a Multispecies Probiotic on Migraine), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04696458 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Effects of a Multispecies Probiotic on Migraine: A Randomized Controlled Trial

TypeinterventionalSponsorScripps HealthRan2021 to 2024Enrolled60ConditionsMigraine, Irritable Bowel Syndrome, Headache, MigraineArmsLactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483), Placebo Comparator: Placebo
3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Gut microbes · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Antidiabetic Effects ofNutrients · 2022
    Article
  8. Evolutionary Insights Into Microbiota Transplantation in Inflammatory Bowel Disease.Frontiers in cellular and infection microbiology · 2022
    Review
  9. Article
  10. Administration ofFrontiers in microbiology · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Violeta LorénHealth Sciences Research Institute, University Hospital "Germans Trias i Pujol", Ctra. de Can Ruti. Cami de les escoles s/n, 08916, Badalona, Spain.
Josep ManyéHealth Sciences Research Institute, University Hospital "Germans Trias i Pujol", Ctra. de Can Ruti. Cami de les escoles s/n, 08916, Badalona, Spain. josep.manye@ciberehd.org.
Mari C FuentesAB-Biotics S.A, Autonomous University of Barcelona, Eureka Building, 08193, Bellaterra, Spain.
Eduard CabréCIBER-EHD, 28029, Madrid, Spain.
Isabel OjangurenPathology Department, University Hospital "Germans Trias i Pujol", 08916, Badalona, Spain.
Jordi EspadalerAB-Biotics S.A, Autonomous University of Barcelona, Eureka Building, 08193, Bellaterra, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Use of probiotic therapy is an active area of investigation to treat intestinal disorders. The clinical benefits of the I3.1 probiotic formula (Lactobacillus plantarum (CECT7484, CECT7485) and P. acidilactici (CECT7483)) were demonstrated in irritable bowel syndrome (IBS) patients in a randomized, double-blind, placebo-controlled clinical trial. The aim of this study was to evaluate the therapeutic effects of I3.1 in two experimental models of colitis, a dextran sulfate sodium (DSS)-induced colitis model and an interleukin (IL)-10-deficient mice model. Colitis was induced in 32 8-week-old Balb/c mice by administering 3% (w/v) DSS in drinking water for 5 days. Probiotics were administered orally (I3.1 or VSL#3, 1 × 10

Indexed as

AnimalsColitisDextran SulfateDisease Models, AnimalFemaleHumansInterferon-gammaInterleukin-6Lactiplantibacillus plantarumMaleMiceMice, Inbred BALB CMice, Inbred C57BLProbioticsDextran SulfateInterferon-gammaInterleukin-6ColitisInterferon-gammaInterleukin-6Lactobacillus plantarumPediococcus acidilacticiProbioticsTNF-alpha

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.